Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically proven solid tumor or lymphoma that is not curable by surgery,
radiotherapy, or standard chemotherapy, or for which no curative therapy exists

- Prostate cancer patients must have the following:

- Tumor progression following blockade of both testicular and adrenal androgens

- Serum testosterone in the castrate range (less than 20 ng/mL)

- At least 3 months since prior suramin therapy

- At least 4 weeks since prior flutamide or other antiandrogen medication and no
evidence of response to treatment

- Luprolide should continue if no prior orchiectomy

- No prior or concurrent brain metastases

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- ECOG 0 or 1

Life expectancy:

- At least 3 months

Hematopoietic:

- WBC at least 3,500/mm^3 OR

- Granulocyte count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

- Hemoglobin at least 8 g/dL

Hepatic:

- Hepatitis B surface antigen negative

- PT no greater than 14 seconds

- PTT no greater than 35 seconds

- Bilirubin no greater than 1.5 mg/dL unless due to Gilbert's disease

- SGOT and SGPT no greater than 2.5 times upper limit of normal (ULN)

- Alkaline phosphatase no greater than 2.5 times ULN

- Albumin at least 2.5 g/dL

Renal:

- Creatinine no greater than 1.5 mg/dL OR

- Creatinine clearance at least 50 mL/min

- Corrected calcium at least 8.0 mg/dL, but no greater than 10.7 mg/dL

Cardiovascular:

- No prior myocardial infarction, coronary artery disease (CAD), congestive heart
failure, second or third degree AV block, or cardiac arrhythmias requiring treatment

- No evidence of CAD on EKG

Pulmonary:

- FEV1-1 at least 70% predicted

- DLCO at least 60% predicted

Other:

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- HIV negative

- At least 1 week since active infection requiring antibiotics

- No other medical or psychiatric condition that would preclude study

- No prior or concurrent seizure disorders controlled with medication

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- At least 4 weeks since prior interleukin-2

- At least 4 weeks since other prior biologic therapy for solid tumors or lymphomas

Chemotherapy:

- See Disease Characteristics

- At least 4 weeks since prior bryostatin 1

- At least 4 weeks since other prior chemotherapy for solid tumors or lymphomas

Endocrine therapy:

- See Disease Characteristics

- At least 4 weeks since other prior endocrine therapy for solid tumors or lymphomas

- No absolute requirement for corticosteroids

Radiotherapy:

- See Disease Characteristics

- At least 4 weeks since prior radiotherapy for solid tumors or lymphomas

Surgery:

- See Disease Characteristics

- At least 4 weeks since prior surgery for solid tumors or lymphomas

Other:

- No absolute requirement for nonsteroidal anti-inflammatory drugs or H2 blockers